

EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma

Aparna Gorthi^{1,2}, July Carolina Romero^{1,2}, Eva Loranc², Lin Cao², Liesl A. Lawrence^{1,2}, Elicia Goodale², Amanda Balboni Iniguez^{3,4}, Xavier Bernard^{1,2}, V. Pragathi Masamsetti², Sydney Roston⁵, Elizabeth R. Lawlor⁶, Jeffrey A. Toretsky⁵, Kimberly Stegmaier^{3,4}, Stephen L. Lessnick⁷, Yidong Chen^{2,8,9} & Alexander J. R. Bishop^{1,2,8}

Ewing sarcoma is an aggressive paediatric cancer of the bone and soft tissue. It results from a chromosomal translocation, predominantly t(11;22)(q24;q12), that fuses the N-terminal transactivation domain of the constitutively expressed EWSR1 protein with the C-terminal DNA binding domain of the rarely expressed FLI1 protein¹. Ewing sarcoma is highly sensitive to genotoxic agents such as etoposide, but the underlying molecular basis of this sensitivity is unclear. Here we show that Ewing sarcoma cells display alterations in regulation of damage-induced transcription, accumulation of R-loops and increased replication stress. In addition, homologous recombination is impaired in Ewing sarcoma owing to an enriched interaction between BRCA1 and the elongating transcription machinery. Finally, we uncover a role for EWSR1 in the transcriptional response to damage, suppressing R-loops and promoting homologous recombination. Our findings improve the current understanding of EWSR1 function, elucidate the mechanistic basis of the sensitivity of Ewing sarcoma to chemotherapy (including PARP1 inhibitors) and highlight a class of BRCA-deficient-like tumours.

EWSR1 is an RNA-binding protein that affects RNA metabolism, presumably through its regulation of RNA polymerase II (RNAPII) and coupling with the splicing machinery². There is also evidence that EWSR1 is involved in genome stability³. Despite extensive research on the transcription targets of the fusion of EWSR1 and FLI1 (EWS-FLI1), factors that mediate the chemosensitivity of Ewing sarcoma or the role of EWSR1 have not been well characterized. Compared to control cell lines (Extended Data Fig. 1a), Ewing sarcoma cell lines were acutely sensitive to most forms of damage, including etoposide (topoisomerase II inhibitor) (Fig. 1a). Notably, EWS-FLI1 conferred this chemosensitization (Fig. 1b), beyond the decreased viability caused by knockdown of the oncogene (Extended Data Fig. 1b). Conversely, EWS-FLI1 expression increased chemosensitivity in U2OS osteosarcoma cells (Extended Data Fig. 1c). As independent validation of this finding, the half maximal inhibitory concentration (IC_{50}) of drugs that induced transcription and replication blocks was nearly fivefold lower in EWS-FLI1-associated cancers than in others in a pan-cancer dataset from the Genomics of Drug Sensitivity in Cancer database⁴ (Extended Data Fig. 1d).

Aberrant regulation of transcription is an important source of endogenous DNA damage⁵. To identify pathways that contribute to the chemosensitivity of Ewing sarcoma, we examined gene expression over time after exposure to etoposide. Gene set enrichment analysis contrasting gene expression in Ewing sarcoma and control cells under basal conditions extracted the expected Ewing sarcoma profile along with defects in replication, transcription and repair pathways

(Extended Data Fig. 1e–g). We also identified a subset of genes that were significantly altered in response to damage in IMR90 human lung cells but not Ewing sarcoma (Fig. 1c, Supplementary Table 1); functional annotation analysis revealed significant enrichment for transcription regulation and RNA metabolism genes (Extended Data Table 1a, b). Notably, comparison with genome-wide RNA inhibition (RNAi) survival screens in *Drosophila* Kc167 cells exposed to various damaging agents consistently highlighted RNA metabolism (Extended Data Fig. 1h, Supplementary Table 2), implicating it as a conserved and critical damage survival component.

EWS-FLI1 and EWSR1 are known to interact with each other^{6,7} and with sub-components of the transcriptional machinery^{8,9}. It has previously been suggested that EWS-FLI1 acts in a dominant-negative manner to wild-type EWSR1 in splicing^{7,9}. However, the role of these two proteins in directly controlling RNAPII activity has not been actively studied. The largest subunit of RNAPII is hyperphosphorylated at Ser2 and Ser5 of the heptapeptide repeats in the C-terminal domain (CTD) during active transcription¹⁰; Ser5 phosphorylation (by CDK7/cyclin H) occurs early during initiation and Ser2 phosphorylation (by CDK9/cyclin T1) triggers elongation. FUS, an EWSR1 homologue, has been reported to regulate RNAPII Ser2 phosphorylation¹¹. Therefore, the dysregulated transcriptional response of Ewing sarcoma could be due to EWS-FLI1 interfering with wild-type EWSR1 in regulating transcription. In an *in vitro* kinase assay using purified recombinant proteins, EWSR1 inhibited phosphorylation of the RNAPII CTD by CDK9 (Fig. 1d, Extended Data Fig. 2a) whereas EWS-FLI1 did not (Extended Data Fig. 2b). EWSR1 depletion in U2OS cells increased RNAPII phosphorylation, confirming the results of the kinase assay (Fig. 1e). Immunoblotting of Ewing sarcoma cell lysates indicated high levels of phospho-Ser2/Ser5 RNAPII compared to IMR90 cells (Fig. 1f), and depletion of EWS-FLI1 in TC32 cells significantly decreased RNAPII phosphorylation (Fig. 1g). Notably, wild-type EWSR1 levels were not affected by EWS-FLI1 knockdown. These data suggest that EWS-FLI1 increased basal levels of transcription, either directly, or indirectly by interfering with EWSR1 activity. Accordingly, EWSR1-depleted cells and Ewing sarcoma cell lines and tumours were more sensitive to blockade of transcription by camptothecin (a topoisomerase I inhibitor) (Extended Data Fig. 2c, d).

DNA damage induces global suppression of transcription (involving BRCA1¹²) followed by gradual recovery. We therefore evaluated the transcription response and recovery following etoposide exposure using incorporation of ethynyl uridine (EU) into RNA (Fig. 1h). Unlike IMR90 cells, which displayed a characteristic decrease in EU incorporation two hours post damage followed by recovery, TC32 Ewing

¹Department of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, Texas 78229, USA. ²Geehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, Texas 78229, USA. ³Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA. ⁴The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA. ⁵Departments of Oncology and Pediatrics, Georgetown University, Washington DC 20057, USA.

⁶Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA. ⁷Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio 43205, USA. ⁸Mays Cancer Center, University of Texas Health at San Antonio, Texas 78229, USA. ⁹Department of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, Texas 78229, USA.




Figure 1 | Ewing sarcoma dysregulates transcription in response to damage. **a**, Cell viability following etoposide treatment. Etoposide dose causing 35% lethality (LD₃₅, dotted grey line) was used for further experiments. Mean \pm s.d., $n = 4$ technical replicates, one-way ANOVA. **b**, Etoposide-induced TC32 cytotoxicity after EWS-FLI1 knockdown (siFLI1). $n = 4$ transfection replicates, two-tailed *t*-tests. **c**, Heat map of damage-induced differential gene expression. **d**, CDK9 kinase activity inhibition by recombinant EWSR1 and FUS proteins on CDKtide or CTD substrates. $n = 3$ technical replicates, one-way ANOVA. **e–g**, Levels of phosphorylated Ser2/Ser5 RNAPII in U2OS cells with EWSR1 knockdown (**e**), IMR90 cells versus TC32 cells (**f**), and TC32 cells with EWS-FLI1 knockdown (**g**). **h**, Transcriptional activity after etoposide treatment. Centre at median, $n = 100$ cells, two-way ANOVA. Mean \pm s.e.m., * $P < 0.05$, ** $P < 0.005$.

sarcoma cells showed a significantly higher basal transcription level, similar to that seen in EWSR1-depleted cells (Extended Data Fig. 2e), and a delayed decrease in transcription.

Alterations in regulation of transcription could result in the accumulation of R-loops (three-stranded nucleic acid structures comprising a DNA-RNA hybrid and non-template single-stranded DNA)¹³. Several pieces of evidence advocate a potential role for EWSR1 and EWS-FLI1 in regulating R-loop accumulation: both proteins regulate RNAPII elongation⁹ and interact with splicing machinery^{9,14,15}, each of which is conducive to R-loop formation¹⁶. Using the RNA-DNA hybrid-specific S9.6 antibody to probe genomic DNA, we discovered that Ewing sarcoma cell lines displayed nearly fourfold higher levels of R-loops compared to IMR90 cells (Fig. 2a). RNaseH treatment (Fig. 2a) or RNaseH1 expression (Extended Data Fig. 3a) substantially decreased the R-loop signal. R-loop accumulation was induced by EWSR1 depletion (Fig. 2b) or by EWS-FLI1, as shown by expression in U2OS cells (Fig. 2b) or knockdown in TC32 cells (Extended Data Fig. 3b). A DNA-binding mutant EWS-FLI1 (Extended Data Fig. 3c) also induced accrual of R-loops, suggesting that the N-terminal protein interaction domain that is common to EWSR1 and EWS-FLI1 is important in promoting

R-loop accumulation. Notably, Ewing sarcoma cells did not display a damage-induced reduction in R-loops to the same extent as IMR90 cells (Extended Data Fig. 3d, e), consistent with the EU-incorporation data (Fig. 1h). These results were corroborated by immunofluorescence analysis of nucleoplasmic R-loops (Fig. 2c, Extended Data Fig. 3f).

To further characterize the R-loops present in Ewing sarcoma, we conducted high-throughput sequencing and analysis of genomic DNA-RNA hybrids by immunoprecipitation (DRIP-seq)¹⁷ in Ewing sarcoma and control cell lines with or without damage. RNaseH-treated DNA served as a negative control. We found extensive R-loops throughout the genome in EWSR1-depleted cells compared to control cells (by read coverage and depth), and this difference was greater in Ewing sarcoma cells (Fig. 2d, Extended Data Fig. 4a). Comparison of DRIP-seq and RNA sequencing (RNA-seq) data indicated a predominance of R-loops in regions containing highly expressed genes (Extended Data Fig. 4b). We examined the co-occurrence of reported EWS-FLI1 binding sites¹⁸ with R-loops and found very strong enrichment (Extended Data Fig. 4c), especially at highly expressed genes (top 16%). We also observed an increased propensity for RNAPII binding (by RNAPII chromatin immunoprecipitation and sequencing, ChIP-seq) in the same regions as R-loops compared to surrounding genomic regions (Extended Data Fig. 4c), which was confirmed at well-established R-loop sites (Extended Data Fig. 4d).

Unresolved R-loops are deleterious to the cell, as they potentially block replication machinery progression and result in stalled or collapsed replication forks^{13,16}. Analysis of well-known markers of replication stress indicated elevated basal levels of activated (phosphorylated) ATR, CHK1 and RPA2 in Ewing sarcoma cells (Fig. 2e). Significant sensitivity to ATR inhibition was observed not only in Ewing sarcoma cells (as previously reported¹⁹), but also in EWSR1-depleted U2OS cells (Fig. 2f). RNaseH1 overexpression suppressed ATR pathway activation (Extended Data Fig. 5a) and increased the rate of cell proliferation (Fig. 2g), confirming that replication stress in Ewing sarcoma is due to accumulated R-loops.

R-loop accumulation is generally associated with increased DNA damage and homologous recombination¹³. Ewing sarcoma cells exhibit high levels of DNA damage²⁰ (measured by the P53-binding protein TP53BP1 foci; Fig. 3a, b) compared to IMR90 cells. However, there was an absence of ionizing radiation-induced RAD51 foci (Fig. 3a, c). Basal levels of RAD51 foci were higher in Ewing sarcoma cells than in IMR90 cells (Fig. 3c), although this may reflect increased replication stress²¹. We used the direct-repeat GFP assay (DR-GFP; Extended Data Fig. 5b) integrated into U2OS cells to evaluate endonuclease-induced double strand break (DSB) repair by homologous recombination²². Expression of either EWS-FLI1 or EWS-ERG (the second most common Ewing sarcoma translocation²³) significantly reduced homologous recombination capacity (Fig. 3d). As EWS-FLI1 binds EWSR1 through their shared N-terminal domain⁶, we investigated whether the suppression of homologous recombination was due to a loss of EWSR1 function. As suspected, either expression of the EWSR1 N-terminal domain alone (Fig. 3d) or expression of two independent small inhibitory RNAs (siRNAs) against EWSR1 (Fig. 3e) also reduced homologous recombination frequency.

Given the similarity in phenotypes between Ewing sarcoma and BRCA1/2 mutant breast cancer (Extended Data Table 1c), we investigated whether BRCA1 function was altered in Ewing sarcoma. It is noteworthy that our gene expression analysis, comparing Ewing sarcoma and control cells, identified significant enrichment for a BRCA1-mutated gene set (Extended Data Fig. 1g). Ewing sarcoma cells have robust BRCA1 expression (Extended Data Fig. 5c) with no known mutations. To test a functional absence, we overexpressed BRCA1 and found restored homologous recombination in the context of EWS-FLI1 expression (Fig. 3f), suggesting a functional impairment, but unexpectedly did not do so when EWSR1 was depleted (Fig. 3g).

PARP1 inhibition is synthetic lethal with BRCA1 deficiency in replicating cells^{24,25} owing to the absence of homologous recombination.




Figure 2 | R-loop accumulation in Ewing sarcoma. **a, b,** Fold-difference in genomic R-loops in IMR90 versus Ewing sarcoma cells (**a**) and U2OS cells with indicated transfections (**b**); $n=4$ technical replicates. **c,** Representative immunofluorescence images of nuclei (DAPI), R-loops (S9.6) and nucleolin (nucleolin). Scale bar, 25 μm . **d,** Thirty-five-kilobase region surrounding the SON gene containing RNA-seq (red), RNAPII ChIP-seq (blue), DRIP-seq (black) and RNaseH-treated (RNH) tracks. Etop, etoposide-treated. Track height represents read counts. **e,** Immunoblots of indicated replication stress proteins. **f,** Cell viability response to ATR inhibitor; $n=4$ technical replicates. **g,** Proliferation rate of TC32 cells overexpressing RNaseH1 (RNH1) after ATR inhibition (ATR). EV, empty vector; $n=3$ transfusion replicates. Mean \pm s.e.m., one-way ANOVA compared to IMR90 control, two-tailed *t*-test within each cell line. #, $*P < 0.05$; ##, $**P < 0.005$, # shows significance compared to control (NT).

Thus, impaired BRCA1 function could provide a molecular basis for the high sensitivity of Ewing sarcoma to PARP1 inhibitors such as Olaparib²⁰ (Extended Data Fig. 6a–c) and etoposide-induced DNA breaks. Mutation of TP53BP1 circumvents the need for BRCA1 in homologous recombination, partially restoring homologous recombination and conferring some resistance to chemotherapy²⁶. Depletion of TP53BP1 restored homologous recombination in the presence of either EWSR1 knockdown or EWS-FLI1 expression (Fig. 3h), consistent with a functional deficiency of BRCA1. Knockdown of TP53BP1 also moderately increased resistance to etoposide in Ewing sarcoma cells (Extended Data Fig. 6e). Together, our data indicate that Ewing sarcoma phenocopies BRCA1-deficient tumours and suggest that secondary mutations in TP53BP1 are a potential chemoresistance mechanism.

BRCA1 has been shown to associate with the elongating transcription complex²⁷ and with R-loops²⁸. Sequestration of BRCA1 with transcription complexes could prevent its redistribution to exogenous damage and therefore explain its functional absence in Ewing sarcoma. While overall levels of BRCA1 protein were similar between Ewing




Figure 3 | Functional loss of EWSR1 impairs homologous recombination. **a,** Representative immunofluorescence images of TP53BP1 and RAD51 foci. Scale bar, 25 μm . **b, c,** Number of cells with more than five TP53BP1 (**b**) or RAD51 (**c**) foci. $n=85$ cells, two-tailed *t*-test. **d–h,** Homologous recombination (HR) frequency with indicated transfections (efficiency demonstrated in Extended Data Figs 5d, 6d). $n=3$ transfusion replicates, one-way ANOVA. **i,** Immunoblots for BRCA1 and EWS-FLI1 in subcellular fractions of TC32 cells with EWS-FLI1 knockdown. Mean \pm s.e.m.; #, $*P < 0.05$; ##, $**P < 0.005$, # shows significance relative to control (black bar).

sarcoma and control cells (Extended Data Fig. 6f), comparison of the subcellular fractions of U2OS versus TC32 cells revealed redistribution of BRCA1. Chromatin-bound BRCA1 was particularly enriched in Ewing sarcoma (Fig. 3i), but was substantially reduced by EWS-FLI1 knockdown. EWSR1 depletion did not result in a similar sequestration of BRCA1 in the chromatin fraction, again highlighting the difference between EWSR1 loss and EWS-FLI1 expression with regard to BRCA1 function (Extended Data Fig. 6g).

BRCA1 preferentially associates with phospho-RNAPII in undamaged cells²⁷. Considering the increased amount of phospho-RNAPII in Ewing sarcoma cells, we examined the interaction between endogenous phospho-RNAPII and BRCA1 by co-immunoprecipitation (Fig. 4a, Extended Data Fig. 7a) in nuclear lysates. An increased proportion of phospho-RNAPII was immunoprecipitated by BRCA1 in Ewing sarcoma, highlighting the redistribution of BRCA1 to transcription complexes. This interaction did not diminish following damage as expected²⁷ and seen in control cell lines. We also confirmed the lack of interaction between BRCA1 and unphosphorylated RNAPII. Subsequent to release from the transcription machinery, the association of BRCA1 with the retinoblastoma binding protein 8 (RB8P8 or CtIP) increases to promote removal of TP53BP1²⁹ and DSB repair by homologous recombination. An increase in damage-induced interaction between BRCA1 and CtIP was observed in control but not Ewing sarcoma cells. Confirming the functional impairment of BRCA1 in DSB repair, we performed BRCA1 ChIP in U2OS cells after




Figure 4 | BRCA1 is retained at transcriptional complexes in Ewing sarcoma. **a**, Immunoblots of indicated proteins after BRCA1 immunoprecipitation. **b**, Schematic of qPCR sites within DR-GFP locus relative to break site used to measure BRCA1 occupancy after EWS-FL1 overexpression (graph below); GAPDH serves as negative control. Mean \pm s.e.m., $n=3$ technical replicates; ** $P<0.005$, two-tailed t -test. **c**, Whole-genome heat maps representing correlation between gene expression, RNAPII, BRCA1 binding sites, and DRIP loci ordered by DRIPs, centred on TSS. **d**, Representative immunohistochemistry images showing R-loop staining across a sarcoma tissue microarray. Scale bar, 10 μ m.

endonuclease-induced DSB at the DR-GFP locus and observed a loss of BRCA1 recruitment in cells transfected with EWS-FL1 compared to vector-transfected controls (Fig. 4b).

Finally, we performed an in-depth analysis of the association of BRCA1 with R-loops in control and Ewing sarcoma cell lines with and without exposure to damage (BRCA1 ChIP-seq, Fig. 4c, Extended Data Fig. 8a). BRCA1 binding (Extended Data Fig. 7b, c) decreased significantly upon damage in control cells, but not as much in Ewing sarcoma cells. We detected BRCA1 binding at a well-known R-loop region¹⁷ (Extended Data Fig. 7d, e), with a significant damage-dependent decrease in controls but not in Ewing sarcoma cell lines. Conversely, we also confirmed the presence of R-loops at BRCA1 binding sites (Extended Data Fig. 7f). Genome-wide maps of BRCA1 sites centred on transcription start sites (TSS) indicated that highly expressed gene loci were associated with both BRCA1 and RNAPII localization (Fig. 4c, Extended Data Fig. 8b). There was strong enrichment for BRCA1 and RNAPII binding at R-loops, particularly in the Ewing sarcoma cells (Extended Data Fig. 8c). We found increased co-localization between BRCA1- and RNAPII-bound TSS in Ewing sarcoma (2,569 genes) compared to IMR90 cells (269 genes) (Extended Data Fig. 9a-d), corroborating the co-immunoprecipitation data. We also observed an increase in enrichment (peak height) of these two proteins in TC32 compared to IMR90 cells. Collectively, the above results indicate that in Ewing sarcoma, BRCA1 is retained at stalled

transcription complexes associated with R-loops, presumably to mitigate associated damage.

In summary, our work provides a detailed examination of basal and damage-responsive R-loops in Ewing sarcoma. We delineate the basis of EWS-FL1-mediated chemosensitivity and conclude that interference with wild-type EWSR1 is responsible for a large part of EWS-FL1 function. We confirmed the prevalence of accumulated R-loops in primary Ewing sarcoma tumours compared to other sarcomas by immunohistochemical analysis on a sarcoma tissue microarray stained with S9.6 antibody (Fig. 4d, Extended Data Fig. 10). Mutations in EWSR1 and its homologues are associated with several therapeutically challenging cancers³⁰. It is tempting to speculate that the causal transcription stress phenotypes may extend to these tumours. We envision the use of agents that induce transcription or replication stress as potentially effective augmentative treatment strategies in various tumours³⁰ associated with EWSR1 translocations.

Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 18 September 2015; accepted 11 January 2018.

Published online 7 March 2018.

- Turc-Carel, C., Philip, I., Berger, M. P., Philip, T. & Lenoir, G. M. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). *Cancer Genet. Cytoogenet.* **12**, 1–19 (1984).
- Paronetto, M. P. Ewing sarcoma protein: a key player in human cancer. *Int. J. Cell Biol.* **2013**, 642853 (2013).
- Li, H. et al. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. *J. Clin. Invest.* **117**, 1314–1323 (2007).
- Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Res.* **41**, D955–D961 (2013).
- Kim, N. & Jinks-Robertson, S. Transcription as a source of genome instability. *Nat. Rev. Genet.* **13**, 204–214 (2012).
- Spano, L. et al. Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein. *Oncogene* **22**, 6819–6829 (2003).
- Embree, L. J., Azuma, M. & Hickstein, D. D. Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines. *Cancer Res.* **69**, 4363–4371 (2009).
- Bertolotti, A. et al. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. *Mol. Cell. Biol.* **18**, 1489–1497 (1998).
- Yang, L., Chansky, H. A. & Hickstein, D. D. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. *J. Biol. Chem.* **275**, 37612–37618 (2000).
- Phatnani, H. P. & Greenleaf, A. L. Phosphorylation and functions of the RNA polymerase II CTD. *Genes Dev.* **20**, 2922–2936 (2006).
- Schwartz, J. C. et al. EWS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. *Genes Dev.* **26**, 2690–2695 (2012).
- Hill, S. J. et al. Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. *Genes Dev.* **28**, 1957–1975 (2014).
- Aguilera, A. & García-Muse, T. R. loops: from transcription byproducts to threats to genome stability. *Mol. Cell* **46**, 115–124 (2012).
- Paronetto, M. P., Miñana, B. & Valcárcel, J. The Ewing sarcoma protein regulates DNA damage-induced alternative splicing. *Mol. Cell* **43**, 353–368 (2011).
- Selvanathan, S. P. et al. Oncogenic fusion protein EWS-FL1 is a network hub that regulates alternative splicing. *Proc. Natl. Acad. Sci. USA* **112**, E1307–E1316 (2015).
- Hamperl, S. & Cimprich, K. A. The contribution of co-transcriptional RNA:DNA hybrid structures to DNA damage and genome instability. *DNA Repair (Amst.)* **19**, 84–94 (2014).
- Ginno, P. A., Lott, P. L., Christensen, H. C., Korf, I. & Chédin, F. R-loop formation is a distinctive characteristic of unmethylated human CpG island promoters. *Mol. Cell* **45**, 814–825 (2012).
- Riggi, N. et al. EWS-FL1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. *Cancer Cell* **26**, 668–681 (2014).
- Nieto-Soler, M. et al. Efficacy of ATM inhibitors as single agents in Ewing sarcoma. *Oncotarget* **7**, 58759–58767 (2016).
- Brenner, J. C. et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. *Cancer Res.* **72**, 1608–1613 (2012).
- Zellweger, R. et al. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. *J. Cell Biol.* **208**, 563–579 (2015).
- Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. *Genes Dev.* **13**, 2633–2638 (1999).

23. Sankar, S. & Lessnick, S. L. Promiscuous partnerships in Ewing's sarcoma. *Cancer Genet.* **204**, 351–365 (2011).
24. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* **434**, 913–917 (2005).
25. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* **434**, 917–921 (2005).
26. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nat. Struct. Mol. Biol.* **17**, 688–695 (2010).
27. Krum, S. A., Miranda, G. A., Lin, C. & Lane, T. F. BRCA1 associates with processive RNA polymerase II. *J. Biol. Chem.* **278**, 52012–52020 (2003).
28. Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. *Mol. Cell* **57**, 636–647 (2015).
29. Escribano-Díaz, C. et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. *Mol. Cell* **49**, 872–883 (2013).
30. Riggi, N., Cironi, L., Suva, M. L. & Stamenkovic, I. Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. *J. Pathol.* **213**, 4–20 (2007).

Supplementary Information is available in the online version of the paper.

Acknowledgements We thank F. Chedin for the DRIP-seq protocol and genome-wide restriction enzyme sites file, and R. Crouch, J. Stark and Y. Shioi for plasmids. We are grateful to the UTH-SA/Cancer Center Sequencing core and the Histology & Immunohistochemistry Core at UTH-SA. This work was funded by the NIH (K22ES012264, 1R15ES019128, 1R01CA152063), a Voelcker

Fund Young Investigator Award and CPRIT (RP150445) to A.J.R.B.; CPRIT (RP101491), a Translational Science Training Across Disciplines Scholarship (UTHSA) and an NCI postdoctoral training grant (T32CA148724) to A.G.; CPRIT (RP140105) to J.C.R.; NIH (P30CA054174) to Mays Cancer Center; NCI (R01CA204915) and Curing Kids Cancer to K.S.; NIH CTSA (1UL1RR025767-01, P30CA054174) and CPRIT (RP120685-C2) to Y.C.; NIH (1R01CA140394) to S.L.L. and NIH (1R01CA134605) to E.R.L.

Author Contributions A.G. and A.J.R.B. conceived and designed the study and wrote the manuscript. A.G. conducted the majority of the research. J.C.R. contributed to replication of experiments for homologous recombination and BRCA1 localization. E.G. performed EU incorporation experiments. L.A.L. performed RNaseH rescue of replication stress and EU incorporation experiments. E.L., L.C., V.P.M. and X.B. provided technical support. A.B.I. and K.S. performed EWS-FLI1 knockdown for the phospho-RNAPII experiment. S.R. and J.A.T. provided recombinant EWS-FLI1 protein. Y.C. conducted bioinformatics analysis support. S.L.L. and E.R.L. provided reagents/insights.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Correspondence and requests for materials should be addressed to A.J.R.B. ([bishopa@uthscsa.edu](mailto:bishop@uthscsa.edu)).

Reviewer Information *Nature* thanks B. Braun and the other anonymous reviewer(s) for their contribution to the peer review of this work.

METHODS

Cell culture and transfections. Ewing sarcoma cell lines (TC32, CHLA10 and CHLA258) were obtained from Children's Oncology Group; EWS502 was obtained from S. Lessnick; and SKES1 and RDES were obtained from S. Mooberry. As controls, IMR90 (CCL-186, primary human fetal fibroblast) and U2OS (HTB-96, paediatric osteosarcoma) cell lines were obtained from the American Type Culture Collection (ATCC). IMR90 and U2OS cells were cultured in DMEM (Corning); TC32, EWS502 and RDES cells in RPMI-40 (Corning); SKES1 cells in McCoy's (Corning); and CHLA10 and CHLA258 cells in IMDM (HyClone); all cultured media were supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals) and 1% antibiotic/antimycotic solution (Corning). *Drosophila melanogaster* Kc167 cells were purchased from the *Drosophila* Genomics Resource Center and maintained in Schneider medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum at 22 °C in a humidified chamber. Human cells were maintained at 37 °C in a humidified atmosphere with 5% CO₂ and tested for mycoplasma contamination. Cell lines were procured from reliable sources and additionally TC32, CHAL10, U2OS and DR-GFP U2OS cell lines were authenticated by STR analysis.

All transfections were carried out using Lipofectamine RNAiMax or Lipofectamine 3000 (Invitrogen) following the manufacturer's instructions. For RNaseH1 transfections, 3 × 10⁶ TC32 cells were transfected with 13 µg of plasmid DNA using Amaxa nucleofection (program X-001). Gene knockdowns were performed by reverse transfection whereas plasmid transfections were performed 24 h after seeding. The siRNAs used in this study include: BRCA1 and EWSR1 (Life Technologies), EWSR1, BRCA1, FLI1 and TP53BP1 (Santa Cruz). For some experiments, lentiviral transduction of TC32 cells with control short hairpin RNA (shCtrl) (clone RHZ4743, Life Technologies) or shFLI1 (clone V2THS227524 or V3THS414176, Life Technologies) was performed. EWS-FLI1, EWS-FLI1 R2L2, EWS-ERG, EWSR1 (full length) and shEWSR1 in pMSCV vector were obtained from S. Lessnick. The EWSR1 N-terminal domain in pLX304 vector was purchased from DNASU. GFP-RNaseH1 and FLAG-RNaseH1 plasmids³¹ were a gift from R. Crouch (Eunice Kennedy Shriver National Institute of Child Health and Human Development). HA-BRCA1 was obtained from Y. Shioi (UTH-SA). ISceI in pCAGGS vector was a gift from M. Jasin (Memorial Sloan Kettering Cancer Center) and J. Stark (City of Hope Cancer Center). All siRNA and plasmid transfections were accompanied with control siRNA or empty vector respectively.

Cell viability. Cells were seeded at 30% confluence in 96- or 384-well plates with or without reverse transfection with siRNA. For plasmid expression, cells were transfected in 60-mm dishes first and then split into 96- or 384-well plates. Cells were treated with different drugs or inhibitors on the next day, and cell viability was evaluated after 48–72 h using Celltiter-Glo (Promega). An etoposide dose causing 35% cell death (LD35) was used for most experiments unless indicated otherwise. Each condition was tested at least in triplicate. Chemicals used in cell viability experiments include etoposide (E1383, Sigma), camptothecin (C9911, Sigma), VE-821 (ATR inhibitor, Selleck Chemicals) and Olaparib (PARP1 inhibitor, Selleck Chemicals). Drug screening data from an independently published study⁴ were obtained from <http://www.cancerrxgene.org/>.

Immunoblotting and immunoprecipitation. Whole-cell lysates were prepared using RIPA buffer according to standard protocols. A subcellular protein fractionation kit for cultured cells (Thermo Fisher Scientific) was used to extract nuclear and chromatin fractions. Cell lysates were separated on either precast 3–8% or 4–12% gradient gels (Invitrogen) or laboratory-prepared gels and transferred onto nitrocellulose membrane. All blots were incubated with primary antibodies overnight and developed using enhanced chemiluminescence (Super ECL, Thermo Fisher Scientific). Antibodies used in this study include FLI1 (ab15289, Abcam), EWSR1 (ab133288 and ab54708, Abcam), RNAPII phospho Ser2 (MMS-129R-200, Covance), RNAPII phospho Ser5 (61085, Active Motif), RNAPII (ab817, Abcam), RNA–DNA hybrids (S9.6, ENH001, Kerafast), single-stranded DNA (ssDNA, MAB3034, Millipore), RNaseH1 (15606-1-AP, Proteintech), nucleolin (sc-13057, Santa Cruz), TP53BP1 (A300-272A, Bethyl labs), RAD51 (70-005-EX, Cosmo), ATR phospho Ser428 (cs28539, Cell Signaling), ATR (sc-1887, Santa Cruz), CHK1 phospho Ser317 (cs2344, Cell Signaling), CHK1 (cs2345, Cell Signaling), RPA2 phospho Ser33 (A300-246A, Bethyl labs), RPA2 (ab2175, Abcam), BRCA1 (sc642, Santa Cruz and 07-434, Millipore), CtIP (cs9201, Cell Signaling), Flag-tag (ab1162, Abcam), Tata-binding protein (TBP, ab818, Abcam), β-actin (ab16039, Abcam), β-tubulin (cs2128, Cell Signaling), vinculin (cs13901, Cell Signaling), GAPDH (cs5174, Cell Signaling), lamin B1 (cs9087, Cell Signaling), Sp1 (sc-59, Santa Cruz), histone H3 (cs9715, Cell Signaling) and secondary antibodies goat anti-mouse IgG-HRP (sc-2060, Santa Cruz), goat anti-rabbit IgG-HRP (sc-2030, Santa Cruz) and goat anti-rat IgG-HRP (sc-2065, Santa Cruz). Western blot experiments were repeated with independent sample preparations three to five times.

All co-immunoprecipitation experiments were done with endogenous proteins. In brief, cells from nearly confluent 15-cm plates treated with either vehicle or

an LD₅₀ dose of etoposide for 2 h were collected and lysed in cytosolic extraction buffer (low salt buffer: 20 mM Hepes, pH 7.4, 0.5% Nonidet P-40, 10 mM NaCl supplemented with Halt protease and phosphatase inhibitors) for 30 min on ice. The nuclei were subsequently extracted in a high salt buffer (20 mM Hepes, 0.5% Nonidet P-40, 1.5 mM MgCl₂, 0.5 M NaCl) for 45 min on a rocker at 4 °C. The lysates were then diluted to physiological salt concentration (150 mM NaCl) and incubated for another 45 min. The nuclear lysates (0.5–0.75 mg) were pre-cleared using protein A/G beads and incubated overnight with 2 µg antibody on a rocker at 4 °C. Settled equilibrated protein A/G beads (25 µl) (or protein L for IgM antibody) were then added to the antibody–lysate mixture and incubated for further 6 h. Bound complexes were washed three times in lysis buffer before elution with Invitrogen NuPage loading buffer. Eluted proteins were evaluated by immunoblotting and compared to inputs (10% of the amount used for immunoprecipitation). Co-immunoprecipitation experiments were repeated with biological replicates at least three times in independent sample preparations.

In vitro RNAPII phosphorylation assay. The following purified recombinant proteins were purchased: RNAPII CTD fragment (POLR2A-1149H, Creative BioMart), EWSR1 (TP303709, Origene), FUS (TP301808, Origene) and CDK9/cyclin T1 (PV4131, Thermo Fisher Scientific). The *in vitro* kinase assay was performed using the Adapta kinase assay (PV5099, Thermo Fisher Scientific) according to the manufacturer's instructions. The template used for kinase activity was either 50 µM CDK7/9tide (triheptad repeat peptide) provided in the kit (PV5090, Thermo Fisher Scientific), or 12 ng RNAPII CTD fragment. EWSR1 or FUS (1 µM) was added to the substrate and 10 µM ATP kinase buffer and pre-incubated for 15 min. CDK9/cyclin T1 (1.77 µg/ml) was then added and the kinase reaction was allowed to proceed for a further 45 min. ADP and ATP (10 µM each) served as positive and negative controls, respectively. Finally, EU-labelled antibody and Alexa Fluor-647-labelled tracer were added and the level of ATP consumption was measured 30 min later using BMG Labtech Pherastar microplate reader. Each condition was tested with technical quadruplicates and the overall experiment was repeated at least twice for independent validation.

Transcription recovery assay. Cells grown on fibronectin-coated coverslips were treated with LD₅₀ doses of etoposide for 0, 2 or 16 h, followed by incubation in medium containing 0.5 mM 5-ethynyl uridine (EU, Thermo Fisher Scientific) for 30 min. After incubation, cells were fixed, permeabilized and subjected to Click-iT RNA reaction (Click-iT RNA Alexa Flour 598 Imaging kit, Thermo Fisher Scientific) according to the manufacturer's instructions. Washed coverslips were mounted onto glass slides using ProLong Antifade Mounting Solution with DAPI (Thermo Fisher Scientific) and imaged using a Zeiss microscope at 63×. A minimum of 100 cells was analysed for each condition. Image analysis was performed using ImageJ. The overall experiment was independently verified three times.

Dot blot for R-loops. Restriction enzyme-digested genomic DNA (0.5 µg) was loaded on to pre-wet H⁺ nylon membrane. The membrane was washed twice with dH₂O, rinsed in 2 × SSC buffer and then left to air dry at room temperature. For ssDNA, an additional denaturation step (incubation in 0.5 N NaOH, 1.5 M HCl for 10 min), followed by a 10 min incubation in neutralization buffer (1 M NaCl, 0.5 M Tris-HCl pH 7) was performed. The membrane was then blocked with 1 × TBS containing 5% non-fat dry milk and incubated with the primary antibody (R-loops S9.6 antibody and ssDNA) in blocking buffer overnight. The blots were analysed using ImageJ software or LI-COR Image Studio to measure signal intensity from genomic DNA, RNaseH-treated DNA and ssDNA. ssDNA signal was used to normalize R-loop signal. Dot blot experiments were performed with technical quadruples and repeated at least twice with independent sample preparation for validation.

Immunofluorescence. Cells were seeded on fibronectin-coated coverslips. Following knockdown and/or 6-h etoposide treatment, cells were fixed with 4% paraformaldehyde. For R-loops, a pre-extraction step was carried out by treating the cells with 0.1% Triton-X 100 in PBS for 30 s at room temperature. After permeabilization with Triton-X 100 for 10 min, cells were blocked for 1 h with 1% BSA, 4% goat serum followed by overnight incubation with primary antibodies in blocking buffer. Coverslips were then incubated with Alex Fluor 488/568 conjugated secondary antibodies (Life Technologies). The cells were then stained with DAPI and coverslips were mounted on slides using Vectashield (Vector Labs). Cells were imaged using a Zeiss microscope at 40× or 63×. At least 100 nuclei per dataset were sampled and a minimum of 80 nuclei per condition was used for quantification of immunofluorescence intensity or foci counting. Image analysis was done using Adobe Photoshop software. Immunofluorescence experiments were repeated for validation.

Immunohistochemistry. The sarcoma tissue microarray (T264) was purchased from US Biomax. Tissue microarrays were treated with 1 mM EDTA pH 8 for 40 min at 95 °C followed by a 20-min cool down step. To confirm antibody specificity, slides were incubated with RNaseH (M0297, New England Biolabs)

and RNaseA (EN0531, Thermo Fisher Scientific) enzymes for 1 h and 24 h at 37 °C, respectively, as previously described³². Slides were then rinsed in 1 × Tris buffered saline (TBS) three times. Following endogenous peroxidase blocking, the slides were incubated with S9.6 (1:20,000) for 2 h at room temperature in a moist humidity chamber. Anti-mouse Powervision-HRP Conjugated Polymer from Leica (Cat #PV6114) for 30 min was used for detection. Slides were then developed with DAB for 5 min, rinsed with TBS and counterstained with haematoxylin, dehydrated, cleared and mounted with a synthetic mounting medium. Images were taken on an Olympus sc-100 at 60× magnification or a Motic Digital Slide Scanning System at 40× magnification.

Repair assays. The DR-GFP reporter assay was carried out as previously described²². U2OS cells with stably integrated DR-GFP construct and the endonuclease ISceI expression vector were obtained from M. Jasin (Memorial Sloan Kettering Cancer Center) and J. Stark (City of Hope Cancer Center). In brief, cells were seeded into 24-well plates and transfected with siRNAs or expression vectors or combinations thereof. On the next day, cells were transfected with ISceI expression vector. After 72 h, cells were collected and GFP-positive cells were evaluated by flow cytometry on a BD FACSCanto flow cytometer. Appropriate controls were used and all experiments were performed with transfection triplicates and repeated for independent validation.

BRCA1 ChIP-qPCR at DR-GFP sites. This assay was carried out as previously described³³. In brief, DR-GFP U2OS cells were transfected with EWS-FLI1 or the empty vector control. Twenty-four hours later, a DSB was induced by transfection with ISceI expression vector. Cells were fixed with 1% formaldehyde 16 h later and then washed with ice-cold 0.5% BSA/PBS. Fixed cells were resuspended in lysis buffer (1% SDS, 10 mM EDTA, 0.5 mM EGTA, 50 mM Tris-HCl pH 7.5, 0.2% Triton X-100, protease and phosphatase inhibitor cocktail), and sonicated to achieve a desired median fragment length of 200 bases. Lysates were then diluted in immunoprecipitation buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 7.5, protease and phosphatase inhibitor cocktail). Five per cent of the solution was reserved as input. The remaining pre-cleared lysates were used for overnight immunoprecipitation with either BRCA1 antibody (A300-000, Bethyl Labs) or IgG control (ab37415, Abcam) and pre-washed beads. On the next day, beads were washed with SDS-free RIPA/LiCl buffer (50 mM HEPES pH 7.5, 1 mM EDTA, 0.7% sodium deoxycholate, 1% NP-40, 0.5 M LiCl, protease and phosphatase inhibitor cocktail) followed by washes in 1 × TE buffer. Immunoprecipitated beads were resuspended in elution buffer (1% SDS, 0.1 M sodium bicarbonate) and incubated at 65 °C to reverse the crosslinks. Eluates were further subjected to proteinase K treatment for 2 h at 37 °C and purified using Qiagen. Real-time quantitative PCR (qPCR) was conducted according the protocol below along with the primers described previously^{34,35}.

Quantitative PCR. qPCR was performed on DNA samples obtained either after chromatin immunoprecipitation or DNA–RNA immunoprecipitation using SYBR qPCR Mix (Applied Biosystems) according to the manufacturer's protocol. All reactions were carried out in technical triplicates. The following primers were used for qPCR performed with technical triplicates: *APOE*: FP: 5'-CCGGTGAGAAGCGCAGTCGG-3'; RP: 5'-CCCAAGCCGACCCCC AGTA-3'; *PARP8*: FP: 5'-GGGTGTCTTAGGCAGAACAA-3'; RP: 5'-ATG GAAACCTGTTGGCTTG-3'; *FEN1*: FP: 5'-CCTCTGCCCTTAGAAATCG -3'; RP: 5'-TAGACGCTCTGGAACACTC -3'.

RNAi screens. The RNAi screens with etoposide, bleomycin and MMS were performed as described previously³⁶. Kc167 cells (*Drosophila melanogaster*; 1.2×10^4) were seeded into 384-well plates with Schneider medium and grown at 22 °C in a humidified chamber. Each well of a 384-well plate contained 0.25 µg double-stranded RNA (dsRNA) with 22,915 dsRNA representing the whole library. The top 5% 'survival' hits for each damaging agent were calculated (Supplementary Table 2) as previously described³⁶. Detailed analysis of MMS hits has previously been published³⁷.

RNA-seq and gene expression analysis. IMR90, U2OS, TC32, EWS502, CHLA258 and CHLA10 cell lines were grown in 10-cm dishes to 90% confluence. Samples were collected after 0, 6, 12, 18 or 24 h of etoposide exposure (equitoxic doses leading to 65% viability after 72 h) and RNA extracted using Qiagen RNeasy kit. The quality of RNA samples was analysed using an Agilent 2100 BioAnalyzer. Sequencing libraries were prepared from total RNAs according to Illumina's RNA sample preparation protocol. Samples were barcoded, and pooled and sequenced with a HiSeq 2000 system with the 50 bp paired-end protocol, and with targeted read counts around 30 million reads. Only U2OS samples were sequenced with the 50 bp single-end protocol. We used TopHat2 aligner to map paired reads to the UCSC hg19 genome build. To quantify gene expression, we used HTSeq to obtain raw read counts per gene and then converted to RPKM (read per kilobase of gene length per million reads of the library) according to gene length and total mapped read count per sample. Log₂-transformed RPKM measurement was used as gene expression level. Differential expression analysis and functional annotation

classification were conducted using Gene Set Enrichment Analysis³⁸ (Broad Institute) and DAVID³⁹.

Chromatin immunoprecipitation. Cells were grown to ~80% confluence and treated with etoposide (LD65) for six hours. Chromatin was collected after fixing with 1% formaldehyde and sheared to an average length of 200–1,500 bp using a Branson sonicator. Four hundred micrograms of sheared chromatin was added to 50 µl protein G beads that were pre-incubated with 10 µg antibody: RNAPII (GAH-111, Qiagen), BRCA1 (sc-646, Santa Cruz) and IgG (GAH-111, Qiagen or ab37415, Abcam), for overnight incubation. ChIP DNA was eluted by incubating beads in elution buffer (50 mM Tris pH 8.0, 10 mM EDTA and 1% SDS) overnight at 65 °C, followed by sequential treatments with RNaseA and proteinase K. The final ChIP DNA was purified by phenol/chloroform extraction and ethanol precipitation. These samples were further sheared using a Covaris sonicator to an average length of 350 bp. Library construction and purification was done following the manufacturer's protocol (MicroPlex Library Preparation kit, Diagenode and AgenCourt Ampure XP, Beckman Coulter). Two control and two Ewing sarcoma cell lines were used for sequencing and repeated for validation.

DNA–RNA immunoprecipitation. DRIP was performed according to a previously published protocol¹⁷. In brief, DNA from a nearly confluent 10-cm dish was obtained using proteinase K followed by phenol/chloroform extraction and ethanol precipitation. DNA was subjected to overnight digestion using a cocktail of restriction enzymes (HindIII, EcoRI, BsrGI, XbaI and SspI, NEB). After being cleaned up with phenol/chloroform/ethanol, 4 µg digested DNA with or without RNaseH pre-treatment was used as input for immunoprecipitation using S9.6 antibody (Kerafast). The DNA–antibody complex was incubated for 16 h and allowed to bind protein A/G beads for a further 4 h. Bound DNA fragments were recovered in the elution buffer by incubating with proteinase K at 55 °C for 45 min. Recovered DNA was cleaned using phenol/chloroform/ethanol and resuspended in 10 mM Tris-HCl pH 8.0. Each immunoprecipitation was run in triplicate and samples were pooled for sequencing after sonication.

ChIP and DRIP sequencing and peak identification. Sonicated and size-selected DNAs (immunoprecipitated DNA that was untreated or treated with etoposide or RNaseH, and input DNA) were processed according to the Illumina Genome DNA library preparation protocol, and sequenced with a HiSeq 2000 or a HiSeq 3000 system with 50 bp single-read sequencing protocol. On average, 30–40 million reads were generated for each DNA sample, and then aligned to the UCSC hg19 genome build using BWA. Peak calling was performed using the MACS2⁴⁰ algorithm. Similar to ref. 17, we used a peak calling parameter with fivefold up to 30-fold enrichment over corresponding input DNA as control (MACS2 parameters: -g 2.7e9 -q 0.05 -B -m 5 30).

Determination of consensus ChIP and DRIP regions. The methodology for analysis has previously been described in detail⁴¹. In brief, DRIP regions were first stacked according to their genomic position (within each chromosome), and then regions that were present in at least three DRIP samples (under any condition) were selected. If the next adjacent region was less than 200 bp away, we treated them as being contiguous. Regions smaller than 200 bp were eliminated. With each seed region, we extended it to the longest run within the stack, followed by another merging step between adjacent regions that were less than 200 bp apart. A total of 33,121 DRIP regions were detected. Small DRIP regions were determined by removing samples with strong DRIP peaks (EWS502, CHLA10, and TC32), and then performing the consensus peak detection algorithm again.

ChIP and DRIP region coverage. We quantified DRIP regions by coverage and sequence read count. DRIP regions with greater coverage and higher enrichment (large sequence read count), were indicative of a true DRIP peak. After obtaining the consensus regions, coverage of each sample was defined as:

$$\text{Coverage} =$$

$$\frac{\sum_{\text{all peaks}} \text{Overlap of detected DRIP peaks with consensus regions (bp)}}{\sum_{\text{all consensus peaks}} \text{Consensus regions (bp)}}$$

In other words, the coverage of a given sample is the percentage of consensus peaks that are covered by the original DRIP peaks obtained by the MACS algorithm.

Normalized read counts. To quantify the read counts within the DRIP regions, we first counted short sequence reads within 100-bp tiling bins equally across the entire genome using the BedTools/CoverageBed command. The normalized read count of a given DRIP region was quantified as:

$$\text{Readcount} =$$

$$\frac{(1/N) \sum_{\text{all bins overlap with consensus DRIP regions}} \text{reads in each bin} \times 50/100}{\text{Total number of mapped reads}/10,000,000}$$

in which N is the total number of DRIP peaks. Read count per DRIP region was normalized to 10 million reads per library. By considering read length (50 bp) and bin size (100 bp), the read count unit essentially defines the normalized depth of coverage per 10 million reads per library. Therefore, if we use consensus DRIP regions for all samples, the read count of a given DRIP region becomes comparable between samples.

Gene sets derived from EWS ChIP-seq or other profiling techniques. EWS-FLI1 targeted genes determined by ChIP-seq were extracted from ref. 18. One thousand, seven hundred and eight-five EWS-FLI1 binding sites were reported, which we mapped to 1,314 unique genes.

DRIP-seq and ChIP-seq heat maps. For any given gene set, a heat map of DRIP data, ChIP data and gene expression data was generated for correlation examination. The gene set was provided in a BED format that contains at least five columns: 1) chromosome; 2) genomic start position; 3) genomic end position; 4) unique ID; 5) gene symbol. All genomic data were derived from the UCSC hg19 genome build. If defined by TSS, columns 2 and 3 were ± 100 bp around the TSS defined by the farthest TSSs, when multiple transcripts are defined in the UCSC hg19 'refFlat' table. If the genes were derived from ChIP-seq data, then the genomic positions were simply the DNA binding sites from a given pull-down target. Heat map selects 50 bins (5,000 bp) to the left and right (x -axis) for a given gene set (y -axis), then plots the read count value from white (read count 0) to dark red. Gene set (y -axis) can be sorted by the peak value defined in the following sections.

DRIP-seq. Raw sequence read counts around $\pm 5,000$ bp (50 bins to each side, with bins of 100 bp) were extracted around the centre of each site defined in the gene set. Each gene was also represented by a mean read count over 100 bins. If a specific order for DRIP data was requested, it was sorted again by read count. To generate a colour map, we used a colour scheme as follows: white, no reads; magenta, with detectable read counts; black/dark magenta, height peaks. DRIP-seq data were normalized to 20 million reads per library equivalent.

ChIP-seq. Similar to DRIP-seq data, raw read counts $\pm 5,000$ bp were extracted

around the centre of each site defined in the gene set. Given that BRCA1 binding sites are mostly narrow peaks, we calculated the mean peak height over windows of seven consecutive bins (700 bp), and then took the maximum height over all moving seven-bin windows, or:

$$\text{peak height} = \max_{j=3 \text{ to } 47} \left(\frac{1}{7} \sum_{k=-3}^3 \text{RC}_{j+k} \right)$$

in which RC is the read count of a given bin. By doing so, we allow the ChIP-seq peak to be within the region, but not necessarily situated at the centre, particularly when TSSs or TTSSs were requested. Heat maps were generated using the same colour scheme as for DRIP-seq. The code for rendering the heat maps was written in MATLAB and will be made available upon request.

Gene expression. Gene expression data were extracted using gene symbol matching. Log₂-transformed RPKM was used to represent expression level. The heat map colour scheme is as follows: magenta, higher expression; blue, lower expression.

Kolmogorov–Smirnov test for enrichment. For a given gene list, we sorted ChIP data, gene expression data, DRIP, RNAPII and BRCA1 ChIP data (as shown in Extended Data Fig. 4c) according to ChIP-seq peak height, gene expression level or DRIP-seq mean read count. To demonstrate the concordance of ChIP peaks and DRIP peaks, for example, we hypothesized that if concordance did not exist, then


the DRIP peaks would be uniformly distributed within the gene list. Therefore, we first determined the ChIP peak threshold (peak height >9), DRIP peak threshold (read count > $\mu + \text{MAD} \times 1.89$, in which μ is the median threshold obtained by calculating mean values across a ± 5 -kb region surrounding the peak and MAD is the median absolute deviation for the same) and expression >5. Depending on the number of peaks we got from ChIP-seq (for example), we determined the threshold for expression and DRIP-seq such that both will have the same positive number of peaks or genes, and we then examined their location within gene list and determined whether they are uniformly distributed using the Kolmogorov–Smirnov test. The code for performing the statistical test was written in MATLAB and will be made available upon request.

Statistical analysis. *P* values for analysing cell viability, R-loop intensity, homologous recombination repair and enzyme assays were computed using either Student's *t*-test (two-tailed) or one-way ANOVA with Bonferroni correction for cell line differences at each drug dose in GraphPad Prism software. Where applicable, two-way ANOVA was employed. When performing multiple comparisons, an FDR of 1% was used as cutoff as evaluated using the Benjamini–Hochberg method. $P < 0.05$ or 0.005 was considered significant (marked as *, # or **, ## respectively). No statistical methods were used to predetermine sample size.

Code availability. All custom MATLAB codes are available from the corresponding author upon request.

Data availability. RNA-seq and DRIP-seq datasets have been deposited at the Gene Expression Omnibus (GEO) with accession code GSE68847. For gel source data, see Supplementary Fig. 1. All other data are available from the corresponding author upon request.

31. Suzuki, Y. et al. An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1. *Mol. Cell. Biol.* **30**, 5123–5134 (2010).
32. Sanz, L. A. et al. Prevalent, dynamic, and conserved R-loop structures associate with specific epigenomic signatures in mammals. *Mol. Cell* **63**, 167–178 (2016).
33. Hu, Y. et al. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. *Cancer Discov.* **4**, 1430–1447 (2014).
34. De Luca, P. et al. BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer. *Mol. Cancer Res.* **9**, 1078–1090 (2011).
35. Gorski, J. J. et al. Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. *Nucleic Acids Res.* **39**, 9536–9548 (2011).
36. Wiles, A. M., Ravi, D., Bhavani, S. & Bishop, A. J. An analysis of normalization methods for *Drosophila* RNAi genomic screens and development of a robust validation scheme. *J. Biomol. Screen.* **13**, 777–784 (2008).
37. Ravi, D. et al. A network of conserved damage survival pathways revealed by a genomic RNAi screen. *PLoS Genet.* **5**, e1000527 (2009).
38. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550 (2005).
39. Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protocols* **4**, 44–57 (2009).
40. Zhang, Y. et al. Model-based analysis of ChIP-seq (MACS). *Genome Biol.* **9**, R137 (2008).
41. Liu, R. et al. Computation tools for genome-wide R-loops identification and characterisation. *Int. J. Comput. Biol. Drug Des.* **10**, 123–136 (2017).




Extended Data Figure 1 | See next page for caption.

Extended Data Figure 1 | Characterizing Ewing sarcoma


chemosensitivity. **a**, Cell lines used in the study. **b**, Level of cell death caused by EWS–FLI1 knockdown alone in TC32 cells. Immunoblot shows extent of knockdown; $n = 4$ transfection replicates. **c**, Cell viability of U2OS cells transfected either with empty vector (EV) or EWS–FLI1 for 24 h before etoposide exposure for a further 48 h. Immunoblot shows transfection efficiency; $n = 3$ transfection replicates. **d**, IC₅₀ levels of etoposide or mitomycin in EWS–FLI1 mutant ($n = 16$) versus pan-cancer ($n = 143$) dataset. Brown lines, range of screening concentrations of the drug. Red lines, geometric mean of drug concentration. **e**, Heat map of basal gene expression profile in control and Ewing sarcoma cell lines

after hierarchical clustering. **f, g**, Top enriched pathways from gene set enrichment analysis of the differences between Ewing sarcoma and IMR90 cells are listed (f) and relevant signature plots are illustrated (g). We found differential upregulation of replication stress, BRCA1-mutation driven network and altered transcription regulation pathways in Ewing sarcoma. **h**, Cross-screen pathway comparison of top survival hits from RNAi screens in *Drosophila* Kc167 cells exposed to MMS, bleomycin or etoposide. Nearly a third of the top 5% hits in each screen were genes involved in transcription and RNA metabolism, highlighting the importance of this pathway in DNA damage survival. Mean \pm s.e.m., * $P < 0.05$, ** $P < 0.005$, two-tailed *t*-test.







Extended Data Figure 2 | Aberrant transcription regulation in Ewing sarcoma. **a**, Immunoblot depicting the phosphorylation of RNAPII CTD fragment used as the substrate in Fig. 1d. Recombinant EWSR1 and hypophosphorylated RNAPII are also displayed. **b**, Level of inhibition of CDK9 activity by buffer (vehicle) or recombinant EWS-FLI1 protein on the two RNAPII CTD substrates. The immunoblot on top is confirmation of kinase activity measured by the assay. **c**, Cytotoxicity profile in response to camptothecin in control, Ewing sarcoma and EWSR1-depleted cells.

$n = 4$ technical replicates, one-way ANOVA against IMR90 cells. **d**, IC_{50} levels of camptothecin in EWS-FLI1 mutant ($n = 15$) versus pan-cancer ($n = 132$) dataset. Brown lines, range of screening concentrations of the drug. Red lines, geometric mean of drug concentration. **e**, Transcription restart assay measured in U2OS cells transfected with either scrambled or EWSR1 siRNA. $n = 4$ transfection replicates, two-way ANOVA. Mean \pm s.e.m., * $P < 0.05$, ** $P < 0.005$.




Extended Data Figure 3 | R-loops in Ewing sarcoma. **a**, Quantification of RNA–DNA hybrids in TC32 cells transfected with either empty vector (EV) or RNaseH1 (RNH1). The immunoblot to the right indicates RNaseH1 transfection efficiency; $n = 4$ transfection replicates. **b**, RNA–DNA hybrid levels in TC32 cells with scrambled (siCtrl) or EWS–FLI1 (siFLI1) knockdown; $n = 3$ transfection replicates. **c**, Schematic of the EWS–FLI1 R2L2 construct. Arginine residues 383 and 386 (black bars) in EWS–FLI1 are converted to leucine to render the fusion oncogene deficient in DNA binding. Below is a quantification of RNA–DNA hybrids in U2OS cells expressing empty vector, EWS–FLI1 or EWS–FLI1 R2L2; $n = 4$ transfection replicates. **d, e**, Fold change in RNA–DNA hybrids after damage (etoposide, 6 h) in IMR90 versus Ewing sarcoma cells (**d**) or U2OS cells with either EWSR1 depletion or EWS–FLI1 expression (**e**). NT, no treatment; $n = 4$ technical or transfection replicates. **f**, Quantification of nucleoplasmic RNA–DNA hybrids in the immunofluorescence images ($n = 80$ nuclei) demonstrated a clear increase in overall R-loop intensity in Ewing sarcoma cells. Nucleolin signal was used to subtract nucleolar R-loops. One-way ANOVA. Mean \pm s.e.m., #, * $P < 0.05$, ##, ** $P < 0.005$. # indicates significance of Ewing sarcoma relative to untreated IMR90 cells or transfections relative to U2OS cells.

$n = 4$ transfection replicates. **d, e**, Fold change in RNA–DNA hybrids after damage (etoposide, 6 h) in IMR90 versus Ewing sarcoma cells (**d**) or U2OS cells with either EWSR1 depletion or EWS–FLI1 expression (**e**). NT, no treatment; $n = 4$ technical or transfection replicates. **f**, Quantification of nucleoplasmic RNA–DNA hybrids in the immunofluorescence images ($n = 80$ nuclei) demonstrated a clear increase in overall R-loop intensity in Ewing sarcoma cells. Nucleolin signal was used to subtract nucleolar R-loops. One-way ANOVA. Mean \pm s.e.m., #, * $P < 0.05$, ##, ** $P < 0.005$. # indicates significance of Ewing sarcoma relative to untreated IMR90 cells or transfections relative to U2OS cells.

a**b****c****d**


Extended Data Figure 4 | DRIP-seq data validation. **a**, Quantification of DRIP (coverage of DRIP region multiplied by reads in that region) across all samples. *y*-axis is graphed in logarithmic scale. **b**, Representative whole-genome heat maps centred around TSS ordered by average expression of Ewing sarcoma cells. **c**, Probability density graph plotted with a Gaussian smoothing kernel of the distribution of DRIP peaks and EWS-FLI1 ChIP peaks at EWS-FLI1 bound genes relative to uniform distribution. *n* = 281

genes (top 16%). Inset, *P* values depicting significance of enrichment for each sample. **d**, Fold enrichment of qPCR product from ChIP experiments done with RNAPII antibody in control and Ewing sarcoma cell lines. The primers target well-known R-loop regions within *APOE* and *EGR1* genes. Mean \pm s.e.m., *n* = 3 technical replicates, ****P* < 0.0005, *****P* < 0.00005. One-way ANOVA across cell lines compared to IMR90 cells and two-tailed *t*-test within cell lines.



Extended Data Figure 5 | R-loop-dependent replication stress and recombination defect in Ewing sarcoma. **a**, Representative immunoblots evaluating decrease in ATR kinase pathway activation upon overexpression of RNaseH1 in TC32 cells. **b**, Schematic of the DR-GFP construct integrated into U2OS cells. Below are representative scatter plots


of the gating scheme used to determine percentage of GFP-positive cells after inducing a DSB via *ISceI* vector compared to empty vector. **c**, RNA-seq data of BRCA1 transcript levels in Ewing sarcoma cell lines compared to IMR90 cells. **d**, Immunoblots demonstrating transfection efficiency of indicated siRNA and expression constructs used in Fig. 3f, g.



Extended Data Figure 6 | See next page for caption.




Extended Data Figure 6 | Similarity of Ewing sarcoma to BRCA-deficient tumours. **a**, IC₅₀ levels of olaparib in EWS-FLI1 mutant cells ($n=17$) versus breast cancers ($n=13$) or pan-cancer ($n=147$) dataset. **b**, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean \pm s.d., $n=3$ technical replicates, one-way ANOVA compared to IMR90 cells. **c**, Cell viability plot demonstrating the role of EWS-FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; $n=3$ transfection replicates. **d**, Immunoblots depicting transfection efficiency of indicated siRNA and expression constructs used in Fig. 3h. **e**, TP53BP1 knockdown improved Ewing sarcoma (TC32 cell) survival in response to damage. Immunoblots depict level of TP53BP1 knockdown. $n=4$ transfection

replicates. **f**, Representative immunoblots showing equivalent levels of BRCA1 in whole cell lysates (upper panel) from control and Ewing sarcoma cells with and without etoposide treatment (2 h). The lower panel shows BRCA1 redistribution in subcellular fractions of U2OS or TC32 cells. GAPDH and lamin B1 were used as loading controls for the cytoplasmic and nuclear fractions, respectively. **g**, Immunoblots of whole cell lysates and subcellular fractions from U2OS cells with and without EWSR1 depletion. Data indicated no change in BRCA1 levels with EWSR1 knockdown. Loading controls include: GAPDH for cytoplasm, Sp1 for nuclei and histone H3 for chromatin. Mean \pm s.e.m., ** $P<0.005$, two-tailed t -test at each dose.



Extended Data Figure 7 | Association of BRCA1 with the transcription complex in Ewing sarcoma. **a**, Co-immunoprecipitation: immunoblots of IMR90 and EWS502 nuclear lysates with and without exposure to etoposide (2 h). The left panel indicates 10% of the input used for immunoprecipitation. BRCA1 antibody was used for immunoprecipitation in the middle panel and the rightmost panel indicates specificity of interaction against IgG pulldown. **b**, Real-time qPCR analysis of BRCA ChIP samples from control and Ewing sarcoma cell lines with and without etoposide treatment, using primers within the *FEN1* and *PARP8* genes. **c**, Representative sequencing track image of gene expression (red tracks),


R-loop sites (black and grey tracks) and BRCA1 binding sites (blue tracks) across the *FEN1* gene demonstrating the enrichment of R-loops and BRCA1 in the region amplified by the primers in **b**. **d**, qPCR analysis as in **b** with primers targeting a well-known R-loop region within the *APOE* gene. **e**, Representative sequencing track image as in **c** across the *APOE* gene. **f**, Agarose gel blots evaluating amplicons generated using EWS502 DRIPs with primers against *FEN1* and *PARP8*. NT, no treatment; Etop, etoposide-treated (6 h); RNH, RNaseH-treated samples. Mean \pm s.e.m., $n = 3$ technical replicates, $**P < 0.005$, two-tailed *t*-test.

a**b****c**

Phenotype	P-values of enrichment over IMR90-DRIP
IMR90 DRIP	1.00E+00
IMR90 RNAPII	2.59E-12
U2OS DRIP	0.9959
U2OS RNAPII	1.90E-06
TC32 DRIP	4.94E-08
TC32 RNAPII	4.87E-65
EWS502 DRIP	1.48E-10
EWS502 RNAPII	3.60E-44

Extended Data Figure 8 | Genome-wide heat maps. **a,** Heat maps representing genome-wide localization of RNAPII, BRCA1 and R-loop sites centred on the TSS. The data were sorted by DRIP sites. The upper panel represents untreated (NT) samples and the lower panel represents etoposide (Etop, 6 h) treated samples. There was a clear decrease in BRCA1 and R-loop signal upon damage in the control cell lines, unlike in Ewing sarcoma. **b,** KS plots to demonstrate empirical distribution of the top


13.8% of DRIP and ChIP peaks and higher expression relative to uniform distribution. Data are sorted by BRCA1 ChIP, $n = 3,066$ genes. **c,** P values of statistical comparisons between RNAPII ChIP and R-loop probability distributions for all cell lines against IMR90 DRIP data centred on the TSS. The top 27% of DRIP-seq peaks corresponding to 6,127 genes were used for the analysis and data were sorted by BRCA1 binding sites.



Extended Data Figure 9 | See next page for caption.

Extended Data Figure 9 | Correlation between BRCA1 and RNAPII binding. **a**, Distribution of RNAPII abundance across the genome for IMR90 and TC32 cells. The bars depict the number of RNAPII bound sites as a function of the number of peaks (*y*-axis) and relative abundance (peak height, log-transformed) within these peaks (*x*-axis). The blue bars indicate the total number of peaks determined from RNAPII ChIP-seq and the red bars represent the peaks that co-localize with BRCA1 peaks obtained from BRCA1 ChIP-seq. The data indicated a similar number of RNAPII peaks for TC32 (11,024) compared to IMR90 (9,813), but a greater amount of DNA bound at these peaks, implying increased RNAPII binding. Furthermore, a higher proportion of RNAPII-bound loci also co-localized to BRCA1 binding sites (red bars) in TC32 than in IMR90 cells (23% compared to 2.7%) and there was a clear increase in RNAPII abundance at these sites. **b**, Distribution of BRCA1 abundance across the genome for IMR90 and TC32, similar to **a**. The data indicate a significantly higher number of total BRCA1 peaks in TC32 cells as well as

a significantly higher enrichment of BRCA1 within these peaks in TC32 cells compared to IMR90 cells. The data also suggest that the majority of the BRCA1 peaks were co-localized with RNAPII. **c**, Scatter plots represent the correlation of RNAPII (left) and BRCA1 (right) peak heights between TC32 and IMR90 cells. Data were plotted after being normalized to read count and log-transformed to make comparisons. Loci that are unique to each cell line map to the axes whereas common loci are scattered around the diagonal. The data clearly suggest an increase in enrichment of both RNAPII and BRCA1 in TC32 cells compared to IMR90 cells. **d**, Scatter plots represent the relationship between co-localized BRCA1 and RNAPII peaks as a function of BRCA1 peak height (*x*-axis) and level of expression of the gene associated with these binding sites (*y*-axis). TC32 cells showed a greater than fivefold increase in the number of BRCA1 peaks that were associated with RNAPII at highly expressed genes. Further, as in **b**, there was a greater abundance of BRCA1 (peak height) at these highly expressed genes in TC32 cells than in IMR90 cells.



Extended Data Figure 10 | Immunohistochemical analysis of tissue sections. **a**, Representative images depicting R-loop staining by S9.6 antibody on sections derived from fixed TC32 cell pellets. Sections were treated with buffer (left), RNaseH (middle) or RNaseA (right) after antigen retrieval. The slides demonstrate loss of R-loop signal after treatment with RNaseH, as expected. RNaseA treatment, which at higher salt concentrations specifically cleaves single-stranded RNA, did not result in a significant loss of R-loop signal confirming the specificity of

S9.6 antibody in detecting RNA–DNA hybrids. **b**, Representative images from a pan-sarcoma tissue microarray. The left and centre panels were probed with S9.6 antibody with or without RNaseH treatment. The right panel was stained with secondary antibody alone and serves as a non-specific control. Each row represents images from one tumour indicated on the left. Images were scanned at 40× (bar at the bottom right denotes resolution).

Extended Data Table 1 | Comparison of Ewing sarcoma to normal cells and BRCA-mutant cancers.

a Processes upregulated in IMR90 by etoposide but not in EwS cell lines

Biological Process	P-value
Regulation of cell proliferation	3.895E-10
Regulation of programmed cell death	4.607E-07
Regulation of phosphorylation	2.1199E-07
Positive regulation of gene expression	0.0193

b

Processes downregulated in IMR90 by etoposide but not in EwS cell lines

Biological Process	P-value
Cell cycle	1.51E-35
Mitosis	4.93E-34
Positive regulation of macromolecular metabolic process	9.08E-05
Regulation of gene expression	1.62E-04
Regulation of RNA metabolic processes	2.38E-03

c

Phenotype	BRCA1 mutant cancers	Ewing sarcoma
Sensitivity to DNA damaging agents	✓	✓
Sensitivity to PARP1 inhibitors	✓	✓
Hyperactivation of PARP1	✓	✓
Impaired homologous recombination	✓	✓
Accumulation of R-loops	✓	✓
High expression of EZH2	✓	✓

Significantly enriched pathways obtained from classification based on Gene Ontology annotation of biological processes of genes that were differentially altered between Ewing sarcoma and IMR90 cells. **a**, Differentially upregulated processes in IMR90 but not Ewing sarcoma cells. **b**, Differentially downregulated processes in IMR90 but not Ewing sarcoma cells. **c**, Characteristic hallmarks of BRCA1-mutant breast cancers and whether these phenotypes are similarly observed in Ewing sarcoma.

Life Sciences Reporting Summary

Corresponding author(s): Alexander Bishop

 Initial submission Revised version Final submission

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

► Experimental design

1. Sample size

Describe how sample size was determined.

All experiments were conducted with cell lines with multiple available biological replicates and based on previous experience with specific experimental setup.

2. Data exclusions

Describe any data exclusions.

No tumors/tissues/in-vitro cell line samples were excluded from analysis.

3. Replication

Describe whether the experimental findings were reliably reproduced.

Reported results were tested and confirmed in at least two independent cell lines (considered biological replicates, in at least technical triplicates) in addition to repeating the experiments between 1 to 5 times.

4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

No animal studies reported in this manuscript. Samples were organized into groups based on Ewing sarcoma or non-Ewing sarcoma or whether they were treated or not (chemical treatment/knockdown/overexpression conditions).

5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

Investigators were not blinded to group allocation as no animal/human patient studies were conducted for this manuscript.

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
- A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars

See the web collection on [statistics for biologists](#) for further resources and guidance.

► Software

Policy information about [availability of computer code](#)

7. Software

Describe the software used to analyze the data in this study.

GraphPad Prism was used for display as well as to perform statistical analyses on the data. Sequencing data was processed using TopHat2 aligner, HTSeq, DESeq2 and analyzed using MACS2 and Gene Set Enrichment Analysis software. For more complex statistical analysis (Kolmogorov Smirnov tests), custom scripts were written using Matlab. LICOR ImageStudio was used to record western blot data and Adobe Photoshop was used to process the data for publication. ImageJ was used to quantify the dot blot and western blot bands.

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). *Nature Methods* [guidance for providing algorithms and software for publication](#) provides further information on this topic.

► Materials and reagents

Policy information about [availability of materials](#)

8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

No restrictions. All reagents were either purchased from commercial entities or obtained from independent research investigators.

9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

Only certified and company-validated antibodies were purchased and used in the study.
FLI1: ab15289, Abcam
EWSR1: ab133288 and ab54708, Abcam
RNAPII phospho Ser2: MMS-129R-200, Covance
RNAPII phospho Ser5: 61085, Active Motif
RNAPII: ab817, Abcam
RNA:DNA hybrids: S9.6, ENH001, Kerafast
single stranded DNA: MAB3034, Millipore
RNASEH1: 15606-1-AP, Proteintech
Nucleolin: sc-13057, Santa Cruz
53BP1: A300-272A, Bethyl labs
RAD51: 70-005-EX, Cosmo
ATR phospho Ser428: cs28539, Cell Signaling
ATR: sc-1887, Santa Cruz
CHK1 phospho Ser317: cs2344, Cell Signaling
CHK1: cs2345, Cell Signaling
RPA2 phospho Ser33: A300-246A, Bethyl labs
RPA2: ab2175, Abcam
BRCA1: sc642, Santa Cruz and 07-434, Millipore
CtlP: cs9201, Cell Signaling
BARD1: ab50984, Abcam
FLAG-tag: ab1162, Abcam
Tata Binding protein: ab818, Abcam
β-Actin: ab16039, Abcam
β-Tubulin: cs2128, Cell Signaling
Lamin B1: cs9087, Cell Signaling
GAPDH: cs5174, Cell Signaling
Sp1: sc-59, Santa Cruz
Histone H3: cs9715, Cell Signaling
Vinculin: cs13901, Cell Signaling
Goat anti-mouse IgG-HRP: sc-2060, Santa Cruz
Goat anti-rabbit IgG-HRP: sc-2030, Santa Cruz
Goat anti-rat IgG-HRP: sc-2065, Santa Cruz

For S9.6 antibody (measuring R-loops, controls for IHC such as RNaseH and RNaseA were included as it has not been reported for specificity in IHC. RNaseH treatment was also used in DRIP-Seq and DRIP-PCR as to control for any background effect. For BRCA1 ChIP-seq, we compared results (locations) to published data from Encode to confirm quality and specificity of results.

10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

TC32, CHLA10 and CHLA258 (EwS cell lines): Children's Oncology Group
EWS502 (EwS cell line): Dr. Stephen Lessnick
SKES1, RDES (EwS cell lines): Dr. Susan Mooberry
IMR90 (fibroblast), U2OS (osteosarcoma): ATCC
DR-GFP U2OS: Dr. Maria Jasin and Dr. Jeremy Stark
kc167 (embryonic Drosophila Melanogaster cell line): Drosophila Genomics Resource Center
Source provided in Supplementary Notes (Online Methods), Page i under Cell culture and transfections section.

b. Describe the method of cell line authentication used.

Cell lines were purchased from ATCC or obtained from collaborators/ Children's Oncology Group and not maintained more than 6 months prior to returning to low passage stocks. Following sequencing we confirmed identity using known mutations in the cell lines, in addition to performing STR profiling on TC32, CHLA10, U2OS and DR-GFP U2OS.

c. Report whether the cell lines were tested for mycoplasma contamination.

Cell lines were tested for mycoplasma contamination.

d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

No commonly misidentified cell lines were used in this study.

► Animals and human research participants

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

No animal studies were conducted as part of this research.

Policy information about [studies involving human research participants](#)

12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

No human research participants were enrolled as part of this research.

Flow Cytometry Reporting Summary

Form fields will expand as needed. Please do not leave fields blank.

► Data presentation

For all flow cytometry data, confirm that:

- 1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- 2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- 3. All plots are contour plots with outliers or pseudocolor plots.
- 4. A numerical value for number of cells or percentage (with statistics) is provided.

► Methodological details

5. Describe the sample preparation.

Repair Assays: The well-established DR-GFP U2OS cell line and plasmids were a kind gift from Dr. Maria Jasin and Dr. Jeremy Stark. This cell line contained the DR-GFP construct (Schematic presented in Extended Fig.5b) integrated into the genome. The cell line was maintained in DMEM media. The experiment was conducted as described in the methods section. At the end of the experiment, cells were harvested after trypsinization and resuspended in PBS containing propidium iodide before evaluating them using a flow cytometer.

Further details of the experimental procedures are provided in the Methods section.

6. Identify the instrument used for data collection.

BD FACSCanto RUO Special Order System

7. Describe the software used to collect and analyze the flow cytometry data.

The data was collected and analyzed using the BD FacsDiva software. The final graphs were prepared using GraphPad Prism. Statistics was performed within GraphPad software.

8. Describe the abundance of the relevant cell populations within post-sort fractions.

Not applicable (did not perform sorting)

9. Describe the gating strategy used.

All the DR-GFP flow experiments were gated and analyzed similarly (Extended Data Fig.5b). The FSC/SSC gates defined the single cell population and the GFP/PI gates were used to define the live cell population. The third scatter plot (GFP vs SSC) was used to identify the sub-population of live cells that had undergone successful homologous recombination (GFP positive). The boundaries for negative versus positive GFP cells was defined based on cells transfected with lScel creating a double strand break substrate for homologous recombination) versus the empty vector (pCAGGS, which does not contain the lScel construct and hence no double strand break substrate for recombination).

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

ChIP-seq Reporting Summary

Form fields will expand as needed. Please do not leave fields blank.

► Data deposition

1. For all ChIP-seq data:

a. Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

b. Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

2. Provide all necessary reviewer access links.

The entry may remain private before publication.

3. Provide a list of all files available in the database submission.

GSE68847

GSM1682833_Sample_TC32_NT_Genes_ReadCount.txt.gz
GSM1682834_Sample_TC32_Etop_6_Genes_ReadCount.txt.gz
GSM1682835_Sample_TC32_Etop_12_Genes_ReadCount.txt.gz
GSM1682836_Sample_TC32_Etop_18_Genes_ReadCount.txt.gz
GSM1682837_Sample_TC32_Etop_24_Genes_ReadCount.txt.gz
GSM1682838_Sample_EWS502_NT_Genes_ReadCount.txt.gz
GSM1682839_Sample_EWS502_Etop_6_Genes_ReadCount.txt.gz
GSM1682840_Sample_EWS502_Etop_12_Genes_ReadCount.txt.gz
GSM1682841_Sample_EWS502_Etop_18_Genes_ReadCount.txt.gz
GSM1682842_Sample_EWS502_Etop_24_Genes_ReadCount.txt.gz
GSM1682843_Sample_CHLA258_NT_Genes_ReadCount.txt.gz
GSM1682844_Sample_CHLA258_Etop_6_Genes_ReadCount.txt.gz
GSM1682845_Sample_CHLA258_Etop_12_Genes_ReadCount.txt.gz
GSM1682846_Sample_CHLA258_Etop_18_Genes_ReadCount.txt.gz
GSM1682847_Sample_CHLA258_Etop_24_Genes_ReadCount.txt.gz
GSM1682848_Sample_CHLA10_NT_Genes_ReadCount.txt.gz
GSM1682849_Sample_CHLA10_Etop_6_Genes_ReadCount.txt.gz
GSM1682850_Sample_CHLA10_Etop_12_Genes_ReadCount.txt.gz
GSM1682851_Sample_CHLA10_Etop_18_Genes_ReadCount.txt.gz
GSM1682852_Sample_CHLA10_Etop_24_Genes_ReadCount.txt.gz
GSM1682853_Sample_IMR90_NT_Genes_ReadCount.txt.gz
GSM1682854_Sample_IMR90_Etop_6_Genes_ReadCount.txt.gz
GSM1682855_Sample_IMR90_Etop_12_Genes_ReadCount.txt.gz
GSM1682856_Sample_IMR90_Etop_18_Genes_ReadCount.txt.gz
GSM1682857_Sample_IMR90_Etop_24_Genes_ReadCount.txt.gz
GSM1682858_Sample_U2OS_NT_Genes_ReadCount.txt.gz
GSM1682859_Sample_U2OS_Etop_6_Genes_ReadCount.txt.gz
GSM1683483_TC32_NT_vs_Input_peaks.bed.gz
GSM1683484_TC32_Etop_vs_Input_peaks.bed.gz
GSM1683485_TC32_RNH_vs_Input_peaks.bed.gz
GSM1683487_EWS502_NT_vs_Input_peaks.bed.gz
GSM1683488_EWS502_Etop_vs_Input_peaks.bed.gz
GSM1683489_EWS502_RNH_vs_Input_peaks.bed.gz
GSM1683491_CHLA10_NT_vs_Input_peaks.bed.gz
GSM1683492_CHLA10_Etop_vs_Input_peaks.bed.gz
GSM1683493_CHLA10_RNH_vs_Input_peaks.bed.gz
GSM1683495_IMR90_NT_vs_Input_peaks.bed.gz
GSM1683496_IMR90_Etop_vs_Input_peaks.bed.gz
GSM1683497_IMR90_RNH_vs_Input_peaks.bed.gz
GSM1683499_U2OS_pMSCV_NT_vs_Input_peaks.bed.gz

GSM1683500_U2OS_pMSCV_Etop_vs_Input_peaks.bed.gz
GSM1683501_U2OS_siCtrl_NT_vs_Input_peaks.bed.gz
GSM1683502_U2OS_siCtrl_Etop_vs_Input_peaks.bed.gz
GSM1683503_U2OS_siEWSR1-1_NT_vs_Input_peaks.bed.gz
GSM1683504_U2OS_siEWSR1-1_Etop_vs_Input_peaks.bed.gz
GSM1683505_U2OS_siEWSR1-2_NT_vs_Input_peaks.bed.gz
GSM1683506_U2OS_siEWSR1-2_Etop_vs_Input_peaks.bed.gz
GSM1683507_U2OS_RNH_vs_Input_peaks.bed.gz
GSM2327769_TC32_RNAp2_ChIP_peaks.bed.gz
GSM2327770_TC32_etop_RNAp2_ChIP_peaks.bed.gz
GSM2327771_TC32_BRCA1_ChIP_2nd_peaks.bed.gz
GSM2327772_TC32_etop_BRCA1_ChIP_peaks.bed.gz
GSM2327775_EWS502_cntl_RNAp2_ChIP_peaks.bed.gz
GSM2327776_EWS502_etop_RNAp2_ChIP_peaks.bed.gz
GSM2327777_EWS502_cntl_BRCA1_ChIP_peaks.bed.gz
GSM2327778_EWS502_etop_BRCA1_ChIP_peaks.bed.gz
GSM2327781_IMR90_cntl_RNAp2_ChIP_peaks.bed.gz
GSM2327782_IMR90_etop_RNAp2_ChIP_peaks.bed.gz
GSM2327783_IMR90_cntl_BRCA1_ChIP_peaks.bed.gz
GSM2327784_IMR90_etop_BRCA1_ChIP_peaks.bed.gz
GSM2327787_U2OS_RNAp2_ChIP_peaks.bed.gz
GSM2327788_U2OS_etop_RNAp2_ChIP_peaks.bed.gz
GSM2327789_U2OS_BRCA1_ChIP_peaks.bed.gz
GSM2327790_U2OS_etop_BRCA1_ChIP_peaks.bed.gz
GSM2690570_TC32_RNAp2_ChIP_peaks.bed.gz
GSM2690571_U2OS_RNAp2_ChIP_peaks.bed.gz

4. If available, provide a link to an anonymized genome browser session (e.g. [UCSC](#)).

► Methodological details

5. Describe the experimental replicates.
6. Describe the sequencing depth for each experiment.
7. Describe the antibodies used for the ChIP-seq experiments.

All ChIP-seq and DRIP-seq experiments were done with biological replicates (multiple Ewing cell lines or two independent siRNA against the same target).

ChIP samples were amplified by PCR through 40 cycles. Samples were then processed as 50bp single-end sequencing. ChIP-seq and DRIP-seq were sequenced with 30-50 million reads for each sample.

Application: DRIP-seq
Antibody against: RNA:DNA hybrids
Supplier: Kerafast
Catalog Number: ENH001
Clone number: S9.6
Validation: The specificity of the antibody was validated by: (1) References listed on the company website (<https://www.kerafast.com/product/1552/anti-dna-rna-hybrid-s96-antibody>), (2) Using samples treated with RNASEH to demonstrate specificity to mark RNA:DNA hybrids, and (3) ChIP-qPCR on known R-loop sites as well as sites that are known to not have R-loops.

Application: ChIP-seq
Antibody against: BRCA1
Supplier: Santa Cruz
Catalog Number: sc-646
Clone: I-20
Lot number: G2115
Validation: This antibody has been validated for use in ChIP-seq by the supplier. Product citation (EMBO J. 2014 Apr 16; 33(8): 890–905.)

Application: ChIP-seq
Antibody against: IgG (Rabbit)
Supplier: Abcam
Catalog number: ab37415
Lot number: GR207305-1
Validation: The antibody was used as a negative control for BRCA1 ChIP-seq. It has been validated previously for use in ChIP-seq experiments according to the supplier's website. (Citation: Nucleic Acids Res 45:1091-1104 (2017))

Application:ChIP-seq
Antibody against: RNAPII
Supplier: Qiagen
Catalog number: GAH-111 (334481)
Lot number: HY06
Validation: This antibody was obtained from the manufacturer validated Epitext ChIP antibody kit where the RNAPII antibody used is the positive control and IgG is the negative control antibodies provided in the kit.

Application:ChIP-seq
Antibody against: IgG (Mouse)
Supplier: Qiagen
Catalog number: GAH-111 (334481)
Lot number: EZ07
Validation: This antibody was obtained from the manufacturer validated Epitext ChIP antibody kit where the RNAPII antibody used is the positive control and IgG is the negative control antibodies provided in the kit.

8. Describe the peak calling parameters.

mac2 callpeaks -g 2.7e9 -q 0.05 -B -m 5 30

9. Describe the methods used to ensure data quality.

Data quality was controlled with FDR < 0.05, and peak enrichment between 5 to 30. Results were further examined using CEAS algorithm to see the enrichment at promoter regions ($p < 0.01$) and at top 10% highly expressed genes. Detailed description of analysis methodology has been provided in the Methods section of the manuscript.

10. Describe the software used to collect and analyze the ChIP-seq data.

We used BWA aligner (default parameters) to align sequence reads to UCSC hg19, and MACS2 to perform peak calling, and CEAS for peak annotation. Detailed description of analysis methodology has been provided in the Methods section of the manuscript.

CORRECTIONS & AMENDMENTS

CORRECTION

<https://doi.org/10.1038/s41586-018-0230-z>

Author Correction: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma

Aparna Gorthi, July Carolina Romero, Eva Loranc, Lin Cao, Liesl A. Lawrence, Elicia Goodale, Amanda Balboni Iniguez, Xavier Bernard, V. Pragathi Masamsetti, Sydney Roston, Elizabeth R. Lawlor, Jeffrey A. Toretsky, Kimberly Stegmaier, Stephen L. Lessnick, Yidong Chen & Alexander J. R. Bishop

Correction to: *Nature* <https://doi.org/10.1038/nature25748>, published online 7 March 2018.

In this Letter, the sentence beginning “This work was funded....” in the Acknowledgements should have read “CPRIT (RP140105) to J.C.R.” rather than “CPRIT (RP150445) to J.C.R.” This error has been corrected online.